Dawson James analyst Jason Kolbert maintained a Buy rating on Athersys (ATHX – Research Report) on May 20 and set a price target of $7.00. The company’s shares closed last Friday at $0.26, close to its 52-week low of $0.25.
According to TipRanks.com, Kolbert is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.4% and a 34.4% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Athersys with a $4.33 average price target, which is an 1190.2% upside from current levels. In a report issued on May 6, Needham also maintained a Buy rating on the stock with a $5.00 price target.
Athersys’ market cap is currently $67.13M and has a P/E ratio of -0.73.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATHX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
Read More on ATHX: